News Category Search | MedStar Health

Featured News

  • November 30, 2021

    Washington, D.C., November 30, 2021 – MedStar Heart & Vascular Institute physicians at MedStar Washington Hospital Center have completed their 300th implant of the HeartMate 3 Left Ventricular Assist Device (LVAD), which treats patients with advanced heart failure. MedStar Washington is among the first four LVAD programs nationwide to reach this historic milestone.

    MedStar Washington Hospital Center participated in the MOMENTUM 3 clinical trial and its post-pivotal study Continuous Access Protocol (CAP), testing the efficacy of the HeartMate 3 LVAD for safety and sustainability as short- and long-term support for patients with advanced (stage D) heart failure. The FDA approved the HeartMate 3 device as a bridge-to-transplant, or as destination therapy treatments. As a result of the trials, the HeartMate 3 pump became the most-often used LVAD therapy with high success rates and lower complication rates.

    “Over the last two decades, LVADs have revolutionized the way we treat patients with stage D heart failure. With a modern technological design that includes full magnetic levitation of the impeller, this pump represents the best LVAD our field has ever seen,” said Ezequiel Molina, MD, surgical director of the Advanced Heart Failure Program at MedStar Washington Hospital Center. “The HeartMate 3 device is a small, more portable and quieter LVAD than previous generations. Patients enjoy longer survival, experience fewer complications, and return to a fairly active lifestyle. And that is our goal – to improve the quality of life of our patients.”

    Many heart failure patients rely on LVADs, which are heart mechanical support devices that can keep blood pumping throughout the body when medications are no longer effective. LVADs can mean the difference between life and death for patients whose hearts are too weak to pump blood adequately on their own. These devices are an effective option as a patient waits for a heart transplant or as long-term treatment.

    MedStar Washington Hospital Center is one of the most experienced LVAD programs in the country, implanting more than 80 devices each year. It has been at the forefront of all the major clinical trials to test new devices. In 1988, it became one of the first four hospitals in the world to implant this potentially game-changing technology in mechanical circulatory support. To date, MedStar Washington has successfully implanted more than 800 VADs.

     


    MedStar Washington Hospital Center is a not-for-profit, 912-bed, teaching and research hospital in the nation’s capital, and is a major referral center for treating the region’s most complex cases. Its cardiology program is highly acclaimed, and its cardiac surgery program has consistently earned the highest national rating–three stars–from the Society of Thoracic Surgeons. MedStar Washington operates the region’s first Comprehensive Stroke Center and the District’s only Cardiac Ventricular Assist Device program, both certified by The Joint Commission. The hospital is also home to MedSTAR, a nationally verified level I trauma center with a state-of-the-art fleet of helicopters and ambulances, and also operates the region’s only adult Burn Center.

Share this

MedStar Health makes the news

All News

  • November 30, 2021

    Washington, D.C., November 30, 2021 – MedStar Heart & Vascular Institute physicians at MedStar Washington Hospital Center have completed their 300th implant of the HeartMate 3 Left Ventricular Assist Device (LVAD), which treats patients with advanced heart failure. MedStar Washington is among the first four LVAD programs nationwide to reach this historic milestone.

    MedStar Washington Hospital Center participated in the MOMENTUM 3 clinical trial and its post-pivotal study Continuous Access Protocol (CAP), testing the efficacy of the HeartMate 3 LVAD for safety and sustainability as short- and long-term support for patients with advanced (stage D) heart failure. The FDA approved the HeartMate 3 device as a bridge-to-transplant, or as destination therapy treatments. As a result of the trials, the HeartMate 3 pump became the most-often used LVAD therapy with high success rates and lower complication rates.

    “Over the last two decades, LVADs have revolutionized the way we treat patients with stage D heart failure. With a modern technological design that includes full magnetic levitation of the impeller, this pump represents the best LVAD our field has ever seen,” said Ezequiel Molina, MD, surgical director of the Advanced Heart Failure Program at MedStar Washington Hospital Center. “The HeartMate 3 device is a small, more portable and quieter LVAD than previous generations. Patients enjoy longer survival, experience fewer complications, and return to a fairly active lifestyle. And that is our goal – to improve the quality of life of our patients.”

    Many heart failure patients rely on LVADs, which are heart mechanical support devices that can keep blood pumping throughout the body when medications are no longer effective. LVADs can mean the difference between life and death for patients whose hearts are too weak to pump blood adequately on their own. These devices are an effective option as a patient waits for a heart transplant or as long-term treatment.

    MedStar Washington Hospital Center is one of the most experienced LVAD programs in the country, implanting more than 80 devices each year. It has been at the forefront of all the major clinical trials to test new devices. In 1988, it became one of the first four hospitals in the world to implant this potentially game-changing technology in mechanical circulatory support. To date, MedStar Washington has successfully implanted more than 800 VADs.

     


    MedStar Washington Hospital Center is a not-for-profit, 912-bed, teaching and research hospital in the nation’s capital, and is a major referral center for treating the region’s most complex cases. Its cardiology program is highly acclaimed, and its cardiac surgery program has consistently earned the highest national rating–three stars–from the Society of Thoracic Surgeons. MedStar Washington operates the region’s first Comprehensive Stroke Center and the District’s only Cardiac Ventricular Assist Device program, both certified by The Joint Commission. The hospital is also home to MedSTAR, a nationally verified level I trauma center with a state-of-the-art fleet of helicopters and ambulances, and also operates the region’s only adult Burn Center.

  • September 08, 2021

    CLINTON, Md. – MedStar Southern Maryland Hospital Center is pleased to welcome Brian C. Case, MD, FACC, a board-certified and fellowship-trained interventional cardiologist who joined the hospital in August 2021.

    Dr. Case, a Montgomery County native, graduated cum laude from St. George's University School of Medicine in 2012 and then participated in an internship at NYU Langone Hospital-Long Island, formerly known as NYU Winthrop Hospital. Dr. Case completed an extensive residency at MedStar Georgetown University Hospital and was selected as the chief medical resident in 2016 for internal medicine. He then obtained fellowship training through a joint program at both MedStar Georgetown University Hospital and MedStar Washington Hospital Center in Washington, D.C., where he was honored as a chief cardiology fellow in 2019, followed by two years of combined research and clinical interventional cardiology.

    As part of the specialty care provided at MedStar Southern Maryland in Clinton, Maryland, Dr. Case treats patients with coronary artery disease through modern technological interventions such as intravascular imaging and invasive physiology to help guide stent selection, placement and deployment. His training includes performing intravascular ultrasound and optical coherence tomography for intravascular imaging, as well as fractional flow reserves and instantaneous wave-free ratios for evaluation of physiological cardiac ischemia.

    “My hope and goal is to incorporate my experience in training into the clinical practice and daily decision making for our patients here at MedStar Southern Maryland,” Dr. Case said. “In the world of interventional cardiology, using intervascular imaging and invasive physiology on a daily basis will help guide treatment plans and allow us to provide more individualized, high-quality heart care. It's about having transparency and innovation that leads to the best possible outcomes for our patients. Because how we treat people is the heart of what matters."

    For appointments with Dr. Case, please call 301-877-5677. To learn more, visit MedStarHealth.org/Case.

  • August 13, 2021

    Baltimore, MD - Brian T. Bethea, MD, a widely published leader in cardio-thoracic health, has been named Chief of Cardiac Surgery at MedStar Union Memorial Hospital, where he oversees management of the heart surgery program and quality initiatives, effective July 1.

    Dr. Brian Bethea

    Dr. Bethea, who served as vice chief of Cardiac Surgery at MedStar Union Memorial, and the regional chief of Outreach for the Baltimore region, receives the baton from Dr. Michael Fiocco, who is stepping aside from the leadership role after 18 years of service. Among his achievements, under his leadership, the cardiac surgery program earned a coveted three-star rating for coronary artery bypass grafting (CABG) procedures from the Society of Thoracic Surgeons, the highest achievable metric in the United States for the procedure. This put the team in the top seven percent of high-performing hospitals nationwide.

    Dr. Bethea has participated in nearly all major U.S. clinical trials for transcatheter aortic valve replacement, (TAVR), and has been involved in early feasibility trials for transcatheter mitral valve repair and replacement. He was selected to participate in past trials for the mitral and tricuspid valves, including Tendyne™, MitraClip™, ENCIRCLE, and TRILUMINATE.

    He is the only surgeon in Maryland to offer patients the latter two options. He travels the world teaching valve repair and replacement techniques to other surgeons and is widely published in all the major cardiothoracic medical journals. Dr. Bethea was among the first authors to be published on the topic of transcatheter mitral valve replacement–a rapidly evolving and expanding field.

    “Dr. Bethea’s clinical interests involve minimally invasive approaches to valvular and structural heart disease,” said Dr. Stuart Bell, vice president of medical affairs chief medical officer at MedStar Good Samaritan and MedStar Union Memorial Hospitals. “This includes procedures such as TAVR, transcatheter mitral valve repair and replacement, transcatheter tricuspid valve repair and replacement, and multi-arterial coronary revascularization, so his level of expertise in the most advanced technology available for cardiac surgery bring an already quality program to another level. We are very proud of the work he’s heading up here, and excited about what that means for our patients.”

    After earning his medical degree from the University of Oklahoma, he completed his residency in general surgery, followed by a fellowship in cardiac surgery at the Johns Hopkins Hospital.

    “I believe in providing personalized, tailored care to each of my patients. Whether it’s a minimally invasive procedure, an open procedure, or a hybrid approach, my goal is to find the method that will best fit the person, rather than the other way around. Since I have been involved in the development of so many new technologies, I can provide patients with all their options, so we can make an informed decision together. I wholeheartedly believe in a team approach to providing care, and view patients, their families, and their referring physicians as integral members of the care team.”

    Dr. Bethea is board certified in thoracic surgery and is a member of the Society of Thoracic Surgeons.


    About MedStar Health
    At MedStar Health, we use the best of our minds and the best of our hearts to serve our patients, those who care for them, and our communities. Our 30,000 associates and 4,700 affiliated physicians are committed to living this promise through our core SPIRIT values—Service, Patient first, Integrity, Respect, Innovation, and Teamwork—across our more than 300 locations including 10 hospitals, ambulatory, and urgent care centers. As the medical education and clinical partner of Georgetown University, MedStar Health is training future physician leaders to care for the whole person and is advancing care through the MedStar Health Research Institute. From our telemedicine and urgent care services to the region’s largest home health agency, we’re committed to providing high-quality health care that’s also easy and convenient for our patients. At MedStar Health—It’s how we treat people. Learn more at MedStarHealth.org.

  • July 27, 2021

    Only Nationally Ranked Heart Program in the Washington Region

    Washington, D.C. – Once again, MedStar Washington Hospital Center has been recognized among the nation’s top cardiac centers in the 2021-22 U.S. News & World Report “Best Hospitals” rankings. Its Cardiology and Heart Surgery program climbed to No. 30, up seven from last year’s survey. It is the only nationally recognized heart program of its kind in the Washington region. MedStar Washington also received the highest rating possible in aortic valve surgery, heart attack, heart bypass surgery, heart failure, and transcatheter aortic valve replacement (TAVR).

    U.S. News evaluated more than 4,750 medical centers nationwide in 15 specialties and 17 procedures and conditions. In the 15 specialty areas, 175 hospitals were ranked in at least one specialty.

    “Our continuing and ascending stature amongst the best regarded cardiovascular centers in the country is a tribute to the tireless teamwork and dedication of our physicians and associates who strive to put the principle of keeping patients at the heart of everything they do,” said Stuart F. Seides, MD, physician executive director of the MedStar Heart & Vascular Institute. “And to all those patients and their physicians who entrust us with their care, we offer our most sincere gratitude.”

    MedStar Washington Hospital Center, home to MedStar Heart & Vascular Institute, has one of the highest-volume cardiac programs in the nation. It integrates the cardiovascular programs and services of all 10 MedStar Health hospitals and outpatient practices in Maryland, Virginia, and Washington, D.C. Its clinical and research alliance with Cleveland Clinic Heart, Vascular & Thoracic Institute, again ranked No. 1 in the nation by U.S. News, has continued to flourish since 2013.

    U.S. News also cited MedStar Washington’s Urology program as high-performing. Six other common procedures and conditions, chronic obstructive pulmonary disease (COPD), colon cancer surgery, diabetes, kidney failure, pneumonia, and stroke, received the highest ratings, too. "High Performing" is the highest rating U.S. News awards for these types of care that were significantly better than the national average, as measured by factors such as patient outcomes.

     The complete rankings are available at https://health.usnews.com/best-hospitals/rankings.

     

    MedStar Washington Hospital Center is a not-for-profit, 912-bed, teaching and research hospital in the nation’s capital, and is a major referral center for treating the region’s most complex cases. Its cardiology program is highly acclaimed, and its cardiac surgery program has consistently earned the highest national rating–three stars–from the Society of Thoracic Surgeons. MedStar Washington operates the region’s first Comprehensive Stroke Center and the District’s only Cardiac Ventricular Assist Device program, both certified by The Joint Commission. The hospital is also home to MedSTAR, a nationally verified level I trauma center with a state-of-the-art fleet of helicopters and ambulances, and also operates the region’s only adult Burn Center.

  • June 28, 2021
    MedStar Health is pleased to announce the establishment of the J.D. Murphy Jr. Cardio-Oncology Fellowship program at MedStar Washington Hospital Center.
  • April 04, 2021

    Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32.